Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.78 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.64 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.64 |
| ▸ | AURKA | O14965 | 9/20 | 0.58 |
| ▸ | IGF1R | P08069 | 3/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.58 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.57 |
| ▸ | GSK3A | P49840 | 4/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5262378 | 0.88 | GSK3B (1.00) | GSK3BCHEK1NTRK2AURKAIGF1R | |
| SCHEMBL5262926 | 0.81 | GSK3B (0.81) | GSK3BCHEK1NTRK2AURKAIGF1R | |
| SCHEMBL4872174 | 0.79 | HCAR3 (0.63) | AURKAAURKB | |
| SCHEMBL5259759 | 0.79 | BRAF (0.55) | GSK3BAURKAIGF1RMAPK8PTK2 | |
| SCHEMBL5262376 | 0.78 | CHEK1 (1.00) | GSK3BCHEK1NTRK2AURKAIGF1R | |
| SCHEMBL11976937 | 0.78 | ALK (0.63) | IGF1R | |
| SCHEMBL5260463 | 0.77 | GSK3B (0.79) | GSK3BCHEK1NTRK2AURKAIGF1R | |
| SCHEMBL24752371 | 0.77 | GSK3B (0.70) | GSK3BCHEK1NTRK2AURKAMAPK8 | |
| SCHEMBL30184376 | 0.77 | GSK3B (0.70) | GSK3BCHEK1NTRK2AURKAMAPK8 | |
| SCHEMBL5259487 | 0.77 | NPC1 (0.51) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268444-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| CN-1211373-C | 2,4-di (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | disclosed |
| US-6649608-B2 | Cyclin-dependent serine/threonine and focal adhesion kinase inhibitors | ASTRAZENECA AB (SE) | 2003-11-18 | — | — | US | disclosed |
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| CN-1406230-A | 2,4-di (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-03-26 | — | — | CN | disclosed |
| EP-1268444-A1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | AstraZeneca AB (SE) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001064655-A1 | 2, 4-DI(HETERO-)ARYLAMINO (-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | CDK2, CCNI, CDK1 | GSK3B 455/4885CHEK1 62/4885NTRK2 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.